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Abstract
Renovascular hypertension induced by 2 Kidney-1 Clip (2K-1C) is a renin-angiotensin-system (RAS)-dependent model,
leading to renal vascular rarefaction and renal failure. RAS inhibitors are not able to reduce arterial pressure (AP) and/or
preserve the renal function, and thus, alternative therapies are needed. Three weeks after left renal artery occlusion,
fluorescently tagged mesenchymal stem cells (MSC) (26105 cells/animal) were injected weekly into the tail vein in 2K-1C
hypertensive rats. Flow cytometry showed labeled MSC in the cortex and medulla of the clipped kidney. MSC prevented a
further increase in the AP, significantly reduced proteinuria and decreased sympathetic hyperactivity in 2K-1C rats. Renal
function parameters were unchanged, except for an increase in urinary volume observed in 2K-1C rats, which was not
corrected by MSC. The treatment improved the morphology and decreased the fibrotic areas in the clipped kidney and also
significantly reduced renal vascular rarefaction typical of 2K-1C model. Expression levels of IL-1b, TNF-a angiotensinogen,
ACE, and Ang II receptor AT1 were elevated, whereas AT2 levels were decreased in the medulla of the clipped kidney. MSC
normalized these expression levels. In conclusion, MSC therapy in the 2K-1C model (i) prevented the progressive increase of
AP, (ii) improved renal morphology and microvascular rarefaction, (iii) reduced fibrosis, proteinuria and inflammatory
cytokines, (iv) suppressed the intrarenal RAS, iv) decreased sympathetic hyperactivity in anesthetized animals and v) MSC
were detected at the CNS suggesting that the cells crossed the blood-brain barrier. This therapy may be a promising
strategy to treat renovascular hypertension and its renal consequences in the near future.
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Introduction
Renovascular hypertension induced by 2 Kidney-1 Clip (2K-
1C) is a renin-angiotensin-system (RAS)-dependent model, leading
to intrarenal vascular rarefaction and renal failure [1–3]. Previous
studies showed that the increase in circulating levels of Angiotensin
II (Ang II) in the 2K-1C model produces higher appetite and
sodium retention, blood volume expansion and increased systemic
vascular resistance, as well as increased production of aldosterone
and antidiuretic hormone, activation of the sympathetic nervous
system (SNS), proliferation, fibrosis and renal injury, all of which
lead to increased arterial pressure (AP) [4–8]. Indeed, Ang II
activates the NAD (P) H oxidases, which produce superoxide, alter
the bioavailability of nitric oxide and consequently cause greater
oxidative stress and inflammation, contributing to endothelial
dysfunction and vascular remodeling [9–12].
The control of renovascular hypertension is problematic. Many
antihypertensive drugs, including the RAS blockers, are not always
effective, and 60% of patients are refractory to the treatment,
indicating that new approaches are needed. Recent studies have
shown that stem cells have emerged as a new therapy for many
diseases [13–17]. Hematopoietic stem cells and mesenchymal stem
(stromal) cells (MSC) can release growth factors and cytokines,
which may act by a paracrine action on neighboring cells,
stimulating proliferation, survival and angiogenesis by inhibiting
apoptosis, fibrosis and oxidative stress [18]. VEGF, HGF, IGF-1
and adrenomedullin are among the growth factors described, and
when they are administered intravenously all of these factors have
antihypertensive actions, emphasizing the role of stem cells in
reducing systemic AP due to paracrine effects on blood vessels
[18]. However, the mechanisms underlying the effects of MSC in
renovascular hypertension are poorly understood.
Therefore, we determined whether treatment with MSC can
improve the renovascular hypertension, modify RAS components,
restore the renal architecture and microvascular rarefaction in the
ischemic kidney, improve renal function and decrease sympathetic
nerve activity (SNA) in the model 2K-1C. Furthermore, the
tracking of MSC cells at the kidney and Central Nervous System
(CNS) were investigated considering that these two regions are
involved in the generation and maintenance of renovascular
hypertension.
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Materials and Methods
Experimental Protocol
All experimental procedures were approved by the Ethics in
Research Committee of the Federal University of Sao Paulo –
School of Medicine (CEP 1017/10). Male Wistar rats (150–180 g)
from the animal facility of the Federal University of Sao Paulo,
Sao Paulo, Brazil were housed in cages, with free access to rat
chow and tap water, and maintained in a temperature-controlled
environment (23uC) on a 12-h light/dark cycle.
Renovascular Hypertension Model
The animals were anesthetized with intraperitoneal (I.P.)
injections of ketamine and xylazine (40 and 20 mg/kg, respec-
tively) (Vetbrands, Jacareı´, SP, Brazil), and the left renal artery was
partially obstructed with a 0.2 mm silver clip4. The control
animals (SHAM) were submitted to the same surgical procedure
but with no renal artery occlusion.
MSC Isolation and Characterization
MSC were isolated from the tibias and femurs of male Wistar
rats (150 to 180 g) [19]. Flushed cells were subjected to
Histopaque (Sigma, Aldrich, St Louis, MO, USA) density gradient
separation, and the mononuclear fraction was harvested. This
fraction was cultured on plastic dishes in low-glucose DMEM
(Gibco, NY, USA) supplemented with 10% FCS (Emcare,
Campinas, Brazil) until the cells reached 70–80% confluence.
Cells were detached with trypsin and subsequently cultured until
the 7th passage. At the 2nd passage, cells were subjected to
osteogenic and adipocyte differentiation assays. For adipocyte
assay, cells were incubated with DMEM containing low-glucose
and 10% FBS supplemented with dexamethasone (1 mM), IBMX
(0.5 mM), insulin (10 mg/mL), and indomethacin (100 mM) for 3
days, and then culture medium was changed to DMEM
containing only insulin (20 mg/mL) for 21 days. Then, the
differentiated adipocytes were stained with oil red (Figure 1B).
For osteogenic differentiation, MSC were incubated in DMEM
containing low glucose and 10% FCS supplemented with
dexamethasone (0.1 mM), ascorbic acid (0.2 mM), and beta
glycerol phosphate (10 mM) for 28 days and stained with alizarin
(Figure 1C). All reagents were purchased from Sigma, St. Louis,
USA. For animal administration, MSC were obtained from
passage 3 to 7. Immunophenotype assays were performed with
CD73, CD90, CD44 (all from BD Bioscience Pharmingen, San
Diego, CA, USA) and CD34 (Santa Cruz Biotechnology, Inc, CA,
USA) every time before administration at animals. The cells were
analyzed at FACS (FACS Calibur, BD). They were positive for
CD73 (99,8%), CD90 (99,9%) and CD44 (97,6%) and negative for
CD34 (1,7%) (Figure 1D).
MSC Treatment
Animals were divided in the following groups: SHAM (n = 5),
2K-1C (n = 8) and 2K-1C+MSC-treated (n = 7). Three weeks after
left renal artery occlusion or SHAM occlusion, MSC (26105 cells/
animal) were injected weekly into the tail vein (two administrations
at the 3rd and 5th weeks). Animals were sacrificed 6 weeks after
clipping.
Cell Labeling for Tracking Assay
The MSC were incubated with Qtracker 585 nm (Invitrogen,
CA, USA) as recommended by the manufacturer, and then
endovenously injected in three animals of the MSC-treated group
at the 3rd and 5th weeks after surgery. These animals were
sacrificed at the 6th week after MSC administration. Untreated
animals were used as controls. Cortical and medullary sections of
the kidney, medulla oblongata and lungs were passed through a
70 mM cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA).
The cells were washed twice with cold PBS (200 g, 5 minutes),
subjected to flow cytometry (FACSCanto; Becton Dickinson,
Franklin Lakes, NJ, USA) and visualized through a PE filter set.
Recording Blood Pressure and Analysis of the Renal
Sympathetic Nerve Activity (RSNA) in Urethane
Anesthetized Rats
The systolic arterial pressure (SBP) was analyzed every week
after the clipping by tail-cuff plethysmography (Narco Bio-systems,
INC., Houston, TX, USA). In separated series of experiments,
others animals were used to SNA analysis. Animals were divided in
the following groups: SHAM (n = 6), 2K-1C (n = 6) and 2K-
1C+MSC-treated (n = 6). After 6 weeks, the rats was slowly
anesthetized with urethane (1.2 g/kg, i.v.) (Sigma-Aldrich Co, St
Louis, MO, USA) to avoid any change in basal cardiovascular
conditions. The left renal nerve was retroperitoneally exposed and
placed on bipolar silver electrodes. When the conditions for nerve
recording had been established, the nerve and electrode were
covered with paraffin oil. The signal from the renal nerve was
displayed on an oscilloscope (Tektronix, TDS 220, USA), and the
nerve activity was amplified (gain 20 K, Neurolog, Digitimer, UK),
filtered by a band-pass filter (100–1000 Hz), and collected for
display and later analysis using a PowerLab data acquisition
system (ADInstruments, Australia). At the end of the experiments,
the background noise level was determined by hexamethonium
bromide administration (30 mg/kg, i.v.) (Sigma-Aldrich Co, St
Louis, MO, USA). The neural activity was analyzed offline using
the appropriate software (Spike Histogram, ADInstruments -
Australia), the raw nerve signal was passed through a spike
discriminator (PowerLab ADInstruments - Australia) to remove
background noise, and then the total nerve activity expressed in
spikes per second (spikes/s). The basal RSNA was expressed as
spikes/s over a period of 60 s. Only experiments in which the level
of background noise was confirmed at the end of the experiments
following hexamethonium administration and terminal anesthesia
were included in this report.
Assessment of Renal Function
Six weeks after the clipping, the animals were housed in
metabolic cages for 24-hr urine collection, and then the animals
were anesthetized with ketamine and xylazine and aorta blood
samples were collected. Plasma and urinary concentrations of
sodium and potassium (Flame Photometer B462 Micronal, Sao
Paulo, Brazil), creatinine (Labtest Kit, Lagoa Santa, Brazil) and
urinary protein excretion (Sensiprot, Labtest Diagnostics, Lagoa
Santa, Brazil) were determined.
Kidney Morphology and Immunohistochemical Staining
Kidneys were removed and fixed with 10% buffered formalde-
hyde for 24 hr, washed with 70% ethanol for 24 hr and then
embedded in paraffin. Sections were cut with a thickness of 4 mm
and stained with Hematoxylin-Eosin (H&E) and Picrosirius red.
Fibrotic areas were measured using the Image Tool program at a
magnification of 20x. A blinded reviewer compared the 2K-1C
kidneys, treated or not, with the SHAM group.
For immunohistochemical procedures, the kidney slices were
deparaffinized and rehydrated. To expose the antigens, kidney
sections were boiled in a target retrieval solution (TRIS buffer pH
9.0) for 30 min. Endogenous peroxidase activity was blocked with
3% H2O2 for 15 min at room temperature. Nonspecific binding
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was prevented by incubating the sections with a protein blocker
(Dako, CA, EUA). Sections were incubated overnight at 4u C with
a primary mouse anti-aminopeptidase P (JG-12) monoclonal
antibody for endothelial cells (1:1000, eBioscience, San Diego, CA
USA). After washing with TBS, the sections were incubated with
horseradish peroxidase-conjugated polymer (Dako, CA, EUA) for
30 min at room temperature. Slides were rinsed with PBS, and the
sites of antibody-antigen reactions were visualized with 3,3’-
diaminobenzidine (Dako, CA, EUA). The sections were lightly
counterstained with hematoxylin. Analyses were carried out with a
light microscopy (Leica Imaging Systems) using x20 magnification,
and stained proteins were quantified using Corel Photo-Paint 12
and UTHSCSA – ImageTool software. The picture analysis was
done in two phases, being the first phase measure the tissue area
subtracting blank areas on picture, and the second phase was done
calculating the percentage of staining present on first phase
picture.
Figure 1. Adipocyte and osteogenic differentiation and MSC tracking assay. Standard culture (A), differentiated adipocytes containing lipid
droplets visualized by Oil Red coloration (B), and osteocytes exhibiting calcium deposition (C), demonstrated by Alizarin coloration. Magnification:
100x. (D) MSC immunophenotyping. MSCs were isolated and labeled for CD73, CD90, CD44 and CD34. Labeled MSC with fluorescent marker detected
by cytometry of 2K-1C animals (n = 2) and 2K-1C + MSC (n = 2) in the cortex and medulla of the clipped kidney (E), unclipped kidney (F), lung (G) and
medulla oblongata (H). Percentage of labeled cells found in the cortex and medulla of clipped and unclipped kidney, lung and medulla oblongata,
analyzed by FACS (I).
doi:10.1371/journal.pone.0078464.g001
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Protein Expression Levels
Protein levels of angiotensinogen (AGTN), renin, angiotensin-
converting enzyme (ACE), Ang II receptors types 1 (AT1) and 2
(AT2) were determined in the renal medulla of the clipped kidneys
by western blot. Kidney fragments were homogenized (homoge-
nizer, Polytron, Switzerland) in ice-cold buffer (50 mM TRIS,
150 mM NaCl, 1,0% nonidet P-40, 0.5% Deoxicolato de So´dio,
0.1% SDS – pH = 8.0) containing a proteases inhibitor pool
(Sigma Chemical CO, St. Louis, EUA). Total protein was
measured by a modified Lowry method (Bio-Rad DC protein
assay reagents, Bio-Rad, Richmond, California, USA). Protein
samples (50 mg) were separated by size using SDS-PAGE
electrophoresis and electroblotted onto nitrocellulose membrane
(Amersham Pharmacia Biotech, Piscataway, NJ, USA). The
membrane blots were probed with the following primary
antibodies: Anti-AGTN 1:5000 (Abcam, Cambridge, MA, USA),
Anti-ECA 1:5000 (Abcam, Cambridge, MA, USA), Anti-renin
1:100 (Santa Cruz Biotechnology, Inc, CA, USA), Anti-AT1 1:50
000 and Anti-AT2 1:4000 (Proteimax, Cotia, Brazil), all of which
were followed by HRP-conjugated second antibodies. The bands
were visualized using Immobilon Western HRP Substrate
(Millipore Corporation, Billerica, EUA). The bands were quan-
tified using Luminescent Image Analyzer-LAS 4000 and the
Image Gauge V3.1 software (Fuji Photo Film CO, Japan).
Gene Expression Levels
Total RNA was purified from the whole kidneys by the phenol
and guanidine isothiocyanate-cesium chloride method using an
appropriate kit (TRIzol; Gibco BRL, Rockland, MD., USA),
following the manufacturer’s instructions. Two mg of total RNA
were treated with DNase (RQ1 RNase-free DNase; Promega,
Madison, WI, USA), to avoid genomic DNA contamination, and
reverse transcribed into cDNA by the addition of a mixture
containing 0.5 mg/ml of oligo(dT), 10 mM of DTT, 0.5 mM of
deoxynucleoside triphosphates (Amersham Pharmacia Biotech,
Uppsala, Sweden) and 200 U of reverse transcriptase enzyme
(SuperScript RT; Gibco BRL). The mRNA expression levels were
estimated by quantitative real-time PCR (Gene-Amp 5700;
Applied Biosystems, Foster City, CA, USA) using the following
specific primers for each molecule (forward and reverse, respec-
tively): b-actin (59 CCTCTATGCCAACACAGTGC 39 and
59ACATCT-GCTGGAAGGTGGAC 39), TNF-a (5’ CAG
AGC AAT GAC TCC AAA GTA GAC CT 3’ and 5’ CAG
ACC CTC ACA CTC AGA TCA TCT T 3’), interleukin (IL)-10
(5’ GGT TTT CCA AGG AGT TGC TCC 3’ and 5’ ATT GAA
CCA CCC GGC ATC TAC 3’) and IL-1b (5’ TCT-CAA-GCA-
GAG-CAC-AGA-CC3’ and 5’ GAC-AAA-GGC-TTC-CCC-
TGG-AG 3’). Relative expression of the target genes was
normalized with the values obtained for the b-actin housekeeping
gene. PCR product accumulation was monitored using SYBR
Green I intercalating dye (Molecular Probes, Eugene, OR, USA),
which exhibits higher fluorescence upon binding of double-
stranded DNA.
Statistical Analysis
Results are presented as the Mean 6 Standard Error. Data
were evaluated using one-way ANOVA followed by the Tukey’s
post-test method or Newman Keuls’s when appropriate and we
using the two-way ANOVA followed by the Bonferroni’s post-test
to analyze the blood pressure. Statistical significance was defined
as P,0.05.
Results
MSC Localization in Kidney, Medulla Oblongata and Lung
after I.V. Administration
Firstly, we focused on tracking MSC at the cortex and medulla
of the clipped and unclipped kidneys, lungs and medulla
oblongata. MSC labeled with Qtracker were found mainly in
the cortex and medulla of the clipped kidneys and also in the
medulla of the unclipped kidneys. Cells were also detected in the
lungs and medulla oblongata, but to a lesser extent (Figure 1D-
G).
Cell Therapy Prevented the Progressive Increase of Blood
Pressure and Reduced the Renal Sympathetic Nerve
Activity
The SBP was initially recorded by tail-cuff plethysmography
every week before administration of MSC and for an additional 3
weeks after cell therapy. In all groups, baseline levels of SBP were
similar (Figure 2A). SBP increased gradually for 2 weeks after
renal artery clipping and by the 3 rd week, SBP was significantly
elevated in the 2K-1C rats compared with the SHAM group.
MSC administration in the 2K-1C was performed at the end of
the third and fifth weeks. Although SBP was not reduced by MSC
treatment, it prevented the increase in SBP observed in the
untreated 2K-1C rats (Figure 2A). Indeed, we observed
sympathetic hyperactivity in anesthetized animals, when we
measured the RSNA 6 weeks after clipping and the MSC
treatment reduced significantly in the hypertensive rats (Figure
2B).
Renal Functional Parameters
There was no significant change in plasma creatinine levels
among groups (Figure 2C). However, hypertensive animals
developed more proteinuria when compared with the SHAM
animals (1563 vs. 80619 mg/24 h, p,0.05) and MSC treatment
significantly reduced proteinuria in 2K-1C animals (Figure 2D).
As show in Table 1, the plasma Na+ concentration was similar
among groups. Serum K+ levels decreased 6 weeks after clipping,
and MSC treatment caused a rise in serum K+ that reached values
close to the SHAM group. Finally, 2K-1C animals presented with
a significant increase in 24 hr urinary volume, with a decrease in
urinary excretion of Na+, indicating a deficient mechanism of
urinary concentration capacity. MSC treatment improves the
urinary excretion of Na+, but did not correct the urinary volume.
The hypertensive animals showed decreased body weight when to
compare to the SHAM rats (214615 vs. 27266 g), however the
MSC treatment didn’t change these values (22368 vs. 29565 g)
(Figure 2E).
Morphology, Fibrosis and Microvascular Rarefaction of
the Clipped Kidneys were Ameliorated after Treatment
with MSC
By HE staining, the 2K-1C rats showed glomerular atrophy,
and the proximal tubular cells were severely damaged when
compared with the SHAM rats. The damage included widespread
loss of brush border, peritubular capillary congestion and edema
in the cortex and medulla of the clipped kidneys (Figure 3,
panels A, B, D and E). After the treatment with MSC there was
an improvement in the morphology of the clipped kidneys in both
the renal cortex (Figure 3C) and medulla (Figure 3F).
The Picrosirius red staining revealed the presence of collagen in
the cortex, mainly in the medulla of the clipped kidneys of 2K-1C
rats, indicating the presence of a fibrogenesis process when
Renal Hypertension and Mesenchymal Stem Cells
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compared with the SHAM group (Figure 3, panels G, H, J
and K). The 2K-1C-MSC-treated animals showed an impressive
improvement in the medullar tissue with much less collagen
staining, which was similar to the SHAM animals (Figure 3,
panels I and L). Picrossirus-stained areas were quantified and
results are shown in Panels M and N of Figure 3.
Glomerular and peritubular capillary density was analyzed by
JG-12 immunohistochemical staining, which is specific for the
endothelium, and showed a significant decrease in both cortical
and medullary capillaries in 2K-1C animals (Figure 4A, 4B, 4D
and 4E). MSC treatment improved the microvascular rarefaction
of the clipped kidneys in both renal cortex (Figure 4C) and
medulla (Figure 4F). Quantification is shown in Figure 4G and
4H.
MSC Treatment Altered the Protein Expression of
Components of Renin-Angiotensin (RAS) in the Medulla
of Clipped Kidneys
Six weeks after clamping, the expression of AGTN, ACE and
AT1 proteins were elevated in the clipped kidneys compared with
the SHAM animals (49, 30 and 43%, respectively), and AT2 levels
were significantly decreased (60%). The expression of all of these
proteins were normalized after MSC treatment (Figure 5A-E).
Treatment with MSC Leads to Downregulation of
Inflammatory Cytokines in the Medulla of Clipped
Kidneys
qRT-PCR results showed greater expression of the inflamma-
tory cytokines IL-1b and TNF-a in the renal medulla of 2K-1C
rats. After the treatment, the expression levels of each of these
Figure 2. Systolic blood pressure (SBP), renal sympathetic nerve activity (RSNA) and renal functional parameters. (A) SBP expressed
as the mean 6 SEM. *P,0.05 vs. SHAM. +P,0.05 vs. 2K-1C (2-way ANOVA followed by the Bonferroni’s post-test). RSNA (B), plasma creatinine (C),
proteinuria (D) and body weight (E) of SHAM animals (n = 5), 2K-1C animals (n = 7) and 2K-1C + MSC animals (n = 7). *P,0.05 vs. SHAM. +P,0.05 vs. 2K-
1C. (One-way ANOVA followed by the Newman Keuls’s post-test).
doi:10.1371/journal.pone.0078464.g002
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genes were reduced (Figure 6A-B). Although the anti-inflamma-
tory cytokine (IL-10) was unchanged in 2K-1C rats, the MSC
significantly increase the expression levels of IL-10 in 2K-1C
animals (Figure 6C).
Discussion
The main results obtained in this study showed that MSC
therapy in the 2K-1C model (i) prevented the progressive increase
of arterial blood pressure, (ii) improved renal morphology and
microvascular rarefaction, (iii) reduced fibrosis, proteinuria and
inflammatory cytokines, (iv) suppressed the intrarenal RAS in the
medulla of the clipped kidneys, iv) decreased sympathetic
hyperactivity in anesthetized animals and v) MSC were detected
at the CNS suggesting that the cells crossed the blood-brain
barrier.
The bone marrow is the most frequent source of cells used for
clinical repair. The bone marrow mononuclear cell fraction not
only contains a complex assortment of different stem/progenitor
cells, but is also known to migrate to damaged tissues, including
ischemic areas [20]. The bone marrow-derived MSC have been
enthusiastically investigated for their reparative and regenerative
properties since the 1970’s [21,22]. Although in most cases the
cells are administered directly into the damaged tissue, in the
present study they were systemically administered in order to
evaluate whether these cells would reach other potentially
damaged organs and tissues including the CNS, a site potentially
important in this model of renovascular hypertension [11]. Our
results showed that the MSC mainly localized to the clipped
kidneys although they were also detected in the medulla oblongata
in the CNS. This result corroborates the previous studies,
suggesting that the MSC are able to contribute directly to tissue
repair, mainly through paracrine and/or endocrine pathways
[18]. Moreover, considering that this model of renovascular
hypertension is dependent on the activation of SNA and that MSC
were found in the medulla oblongata, we evaluated the role of
SNA in the antihypertensive effect of MSC. In fact, we have
previously observed that the vasomotor sympathetic tone signif-
icantly increased after 4th week [12]. The abnormal activity of
neurons in the medulla oblongata and the presence of MSC in this
region suggest that MSC could cross the blood-brain barrier and
in somehow reduce SNA leading to reduction in blood pressure. In
fact, the treatment with MSC prevented the progressive increase
in SBP in 2K-1C animals. The beneficial effects of this type of cell
therapy was successfully performed in others models of
hypertension [23,24], however, the mechanism by which MSC
minimized the hypertension is not clear. However, the presence of
MSC in the CNS suggests that the effect of this treatment on SBP
could be at least in part be due to an interference with SNA
leading to reduction of sympathetic activity to the cardiovascular
system. Indeed, in our results, we observed that the MSC
treatment reduced renal SNA in 2K-1C rats.
On the other hand, it is well established that the activation of
RAS induced by reduced renal artery flow is imperative to initiate
the increase in SBP, however, the chronic renal hypoperfusion
causes renal damage that, in turn, perpetuates the hypertension.
Six weeks after the clipping, 2K-1C rats presented with significant
proteinuria, indicating that the integrity of the glomerular barrier
was lost by the chronic hypoperfusion. MSC treatment signifi-
cantly reduced proteinuria, suggesting that MSC restored, albeit
partially, the selectivity of the glomerular capillary wall.
The renal architecture was severely damaged by chronic
ischemia, and it was significantly improved by MSC. Interestingly,
the fibrosis marker was higher in the renal medulla when
compared with the renal cortex of the clipped kidneys, and this
behavior may explain the higher amount of MSC observed in the
medulla. In fact, there was an improvement in the morphology of
the clipped kidneys primarily in the medulla after MSC treatment,
and animals indeed showed less fibrosis when compared with the
kidneys of the 2K-1C untreated animals. These partially improved
outcomes were also seen following other diseases, such as acute
kidney injury [14] and the remnant model kidney [13]. Chade et
al (2009) [25] demonstrated that administration of endothelial
progenitor cells (EPC) directly in the clipped kidney (2K-1C) at the
end of the sixth week after clipping improved renal function by
improving vascular remodeling and inducing the expression of
angiogenic factors. EPC were renoprotective and attenuated renal
dysfunction and damage in chronic atherosclerotic renal artery
stenosis and consequently decreased the injury signals [26].
Indeed, previous studies showed that when the kidney is
exposed to chronic renal artery stenosis it results in significant
functional deterioration presented by renal inflammation, fibrosis,
and microvascular rarefaction and remodeling [3,27]. It is known
that intrarenal microvascular disease likely aggravates the
progression of renal injury in renovascular hypertension and
may account for the renal failure. Our results demonstrated that
the density of glomerular and peritubular capillaries was restored
after the treatment with MSC in the cortex and medulla of clipped
kidneys, indicating that these cells play important role in
improving neovascularization improving renal function.
2K-1C animals showed polyuria with a decrease in the net Na+
excretion, indicating that the polyuria was not sodium dependent,
but was most likely caused by a deficient mechanism of urine
concentration. It has been demonstrated that the plasma levels of
ADH are not changed in this model of hypertension [28],
however, the microvascular rarefaction could hinder ADH in
reaching the collecting duct, contributing to an increase in urinary
volume. But, in spite of significant improvement of renal
vascularization, MSC treatment was not effective to correct this
defect. A previous study showed that the expression of AQP 1–3
was significantly decreased in the clipped kidney [29,30]. Thus, a
downregulation of AQPs in the clipped kidney may, in part,
account for the increased urinary volume.
It is well established that 2K-1C is a RAS-dependent model,
and in addition to the systemic activation of RAS, we found that
2K-1C animals presented with an intrarenal upregulation of the
angiotensinogen and AT1 receptor and a downregulation of the
AT2 receptor. We have not determined the intrarenal
Ang II content, but these results suggest that the chronic renal
Table 1. Plasma and urinary parameters.
SHAM 2K-1C 2K-1C + MSC
Plasma values
Na+ (mEq/l) 141,060,5 141,061,0 142,062,4
K+ (mEq/l) 5,560,2 5,060,3a 5,360,2b
Urinary values
Na+ (mEq/24 h) 2,460,1 1,060,3a 2,460,3b
K+ (mEq/24 h) 4,860,1 5,760,3 a 3,261,6
Total urinary volume (ml) 12,060,9 28,064,4 a 33,068,5
Values are expressed as the mean 6 SE.
SHAM (n = 5), SHAM+MSC-treated (n = 2), 2K-1C (n = 8) and 2K-1C+MSC-treated
(n = 7).
aP,0.05 vs. SHAM group. bP,0.05 vs. 2K-1C group.
(One-Way ANOVA following by Newman- Keuls’s pos-test).
doi:10.1371/journal.pone.0078464.t001
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hypoperfusion induced an activation of intrarenal RAS that could
contribute to renal damage. Moreover, Prieto-Carraquero and
cols, in 2008 [31], showed that renal medullary tissue of 2K-1C
rats showed greater levels of renin protein, renin mRNA, Ang I,
Ang II and renin activity than sham rats. These results suggest that
intrarenal RAS contributed to renal inflammation [2] and fibrosis
[32]. MSC treatment normalized the expression of RAS
components, resulting in less inflammation and fibrosis. The
mechanism by which MSC downregulated intrarenal RAS
components is not know at this moment, but it is an important
issue warranting further investigation because the intrarenal RAS
Figure 3. Morphology and fibrosis of the kidney. Hematoxylin-Eosin (H&E) (A-F) and Picrosirius red (G-L) staining (20x) of a renal cortex and
medulla of the clipped kidneys of SHAM, 2K-1C and 2K-1C + MSC animals. Fibrotic area was measured using the Image Tool program (M and N).
*P,0.05 vs. 2K-1C. (One-way ANOVA followed by the Newman Keuls’s post-test.
doi:10.1371/journal.pone.0078464.g003
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activation plays a pivotal role in many kidney diseases, including
diabetic nephropathy.
There is evidence that persistent inflammation contributes to
MSC migration to damaged tissue [33]. Our results showed a
higher expression of IL-1b and TNF-a mRNAs in the renal
medulla of 2K-1C rats, which were significantly reduced in the
animals treated with MSC, together with an increase in the
expression of the anti-inflammatory IL-10. It is well known that
MSC secrete many molecules under inflammatory stimuli.
Growing evidence suggests that the mechanisms by which MSC
lead to this tissue amelioration may be caused by their ability to
undergo to transdifferentiating, fusing, and/or secreting of trophic
factors producing the paracrine effects [22,34].
Conclusion
Our data support the notion that renal injury promotes a critical
signaling mechanism underlying the development of hypertension
in the 2K-1C rat model, and MSC treatment can be a promising
strategy to treat chronic renal ischemia and renovascular
hypertension in the near future.
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Figure 4. Capillary staining. Representative image of JG-12 staining of a renal cortex (20x) and medulla (40X) of the clipped kidney of a SHAM (A
and D), 2K-1C (B and E) and 2K-1C + MSC animal (C and F). Stained areas were measured using the Image Tool program (G and H). The arrows
show the positive staining in the arterioles. *P,0.05 vs. SHAM. +P,0.05 vs. 2K-1C (One-way ANOVA followed by the Tukey’s post-test).
doi:10.1371/journal.pone.0078464.g004
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Figure 5. Expression of components of Renin-Angiotensin (RAS) in the medulla of clipped kidneys. Angiotensinogen (A), Renin (B), ACE
(C), AT1 (D) and AT2 receptors (E) in the medulla of kidney clipped of SHAM (n = 5), 2K-1C (n = 7) and 2K-1C + MSC animals (n = 7). *P,0.05 vs. SHAM.
+P,0.05 vs. 2K-1C (One-way ANOVA followed by the Tukey’s post-test).
doi:10.1371/journal.pone.0078464.g005
Figure 6. Cytokine mRNA expression. (A) IL-1b mRNA expression. (B) TNF-a mRNA expression. (C) IL-10 mRNA expression. Data expressed as
arbitrary units *P,0.05 vs. SHAM. +P,0.05 vs. 2K-1C. (One-way ANOVA followed by the Tukey’s post-test).
doi:10.1371/journal.pone.0078464.g006
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